Cancer Antibody Drug Conjugates Market Insights Video

According to Cognitive Market Research, the global Cancer Antibody Drug Conjugates market size was USD 11524.5 million in 2024. It will expand at a compound annual growth rate (CAGR) of 9.70% from 2024 to 2031.

• North America held the major market share for more than 40% of the global revenue with a market size of USD 4609.80 million in 2024 and will rise at the compound annual growth rate (CAGR) of 7.9% from the year 2024 to 2031.
• Europe accounted for a market share of over 30% of the global revenue with a market size of USD 3457.35 million.
• Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 2650.64 million in 2024 and will rise at the compound annual growth rate (CAGR) of 11.7% from 2024 to 2031.
• Latin America had a market share of more than 5% of the global revenue with a market size of USD 576.23 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031.
• Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 230.49 million in 2024 and will rise at a compound annual growth rate (CAGR) of 9.4% from 2024 to 2031.
• The specialty clinic category is the fastest growing segment of the Cancer Antibody Drug Conjugates industry